When Paxlovid Is “Commercialized” In 2023, Patient Access To The Covid-19 Treatment Will Depend On Insurance Status

The oral tablet Paxlovid (nirmatrelvir/ritonavir) is used to treat Covid-19. The antiviral can prevent Covid-19 infections from becoming severe. As such, it has helped many people infected with Covid-19 from being hospitalized or dying. Until now, the federal government has paid for all doses of…#medicare #medicaid #ashishjha #foodanddrugadministration #responseteam
Source: Reuters: Health - Category: Consumer Health News Source Type: news